[Theragnostics Series: Talk with the Expert]

• Related Link: https://iaea.webex.com/webappng/sites/iaea/webinar/webinarSeries/register/63dd83e6669b4ef39b6560dd68ec3c45

 

This series consists of five planned Q&A webinars:

• 14 November 2024:  Nuts and Bolts of Theranostics (PRE-RECORDED LECTURE ALREADY AVAILABLE)
  Focus: Radioiodine therapy of thyroid cancer
   
• 21 November 2024: Theranostics in Oncology
  Focus: Treatment of painful skeletal metastases with Sr-89 Cl, Sm-154 EDTMP and Ra-223 dichloride
   
• 19 December 2024: Advanced Theranostics in Oncology
  Focus: PRRT with Lu-177 DOTATATE and metastatic prostate cancer with Lu177-PSMA
   
• 9 January 2025: Clinical Research Theranostics
  Focus: Alpha and beta diagnostic/therapeutic pairs, and dose de-escalation trials
   
• TBD: Panel: How to implement a successful theranostic programme in diverse settings
  Focus: Success stories from Africa, the Middle East, and Asia.

 

[ICRP Publication 155 on Specific Absorbed Fractions for Reference Paediatric Individuals]

• Related Link: https://icrp.org/publication.asp?id=ICRP%20Publication%20155&utm_source=International+Commission+on+Radiological+Protection&utm_campaign=75951b1975-EMAIL_CAMPAIGN_2024_11_14_01_08&utm_medium=email&utm_term=0_-75951b1975-233092054&mc_cid=75951b1975&mc_eid=dcd2527837
   

 

Abstract - The calculation of doses to organs and tissues of interest due to internally emitting radionuclides requires knowledge of the time-dependent distribution of the radionuclide, its physical decay properties, and the fraction of emitted energy absorbed per mass of the target. The latter property is quantified as the specific absorbed fraction (SAF). This publication provides photon, electron, alpha particle, and neutron (for nuclides undergoing spontaneous fission) SAF values for the suite of reference individuals.